IN THE CLAIMS


1. (previously presented) A prodrug of the formula:

where A is selenium, and R is a mono- di- or oligo- saccharide.

2. (currently amended) A prodrug of claim 1 wherein R is derived from ribose, galactose, glucose, or mannose.

Claims 3-8 (cancelled)

9. (previously presented) A prodrug of the formula:



where A is selenium, and

R' is a sugar having the formula (CHOH)_nCH₂OH, where n is 1 to 5, or

R' is an alkyl or aryl group, or

R' is =0, and

R[‡] is an alkoxy, or an amine group.

- 10. (original) A prodrug as in Claim 9 wherein R^{\ddagger} is $-OR^{1}$ where R^{1} is ethyl, or methyl.
- 11. (original) A prodrug as in Claim 9 wherein R' is methyl, ethyl, benzyl, carboxyl, or phenyl.

- 12. (original) A prodrug as in Claim 9 wherein R[‡] is -NR[†]₂, wherein the R[†] groups are the same or different and are hydrogen or alkyl.
- 13. (original) A prodrug as in Claim 11 wherein at least one R[†] is methyl.Claims 14 and 15 (cancelled)
- 16. (currently amended) A method for reducing toxicity of a substance the toxic insult in a mammal, comprising administering the prodrug of claim 1 to the mammal.
- 17. (previously presented) A method for (1) reducing unwanted side effects of chemo- or radiotherapy of cancer, (2) improving cardiovascular function, (3) preventing mutagenesis, (4) preventing the initiation and/or progression of cancer, (5) reducing toxic consequences of planned or unplanned radiation or chemical exposures, (6) slowing the aging process, or (7) preventing cataract formation in a mammal comprising administering to the mammal the prodrug of claim 1.
- 18. (currently amended) A method for reducing toxicity of a substance the toxic insult in a mammal, comprising administering to the mammal a prodrug having the formula

$$R^1$$
 R^2
 R^3

wherein

(1) A is selenium,

 R^1 is a sugar having the formula $(CHOH)_nCH_2OH$, where n is 1 to 5, or R^1 is an alkyl or aryl group, or R^1 is =0,

R² is CH₂CH₂CH₂N(R⁴)₂, wherein R⁴ may be the same or different and may be

hydrogen, alkyl, alkoxy, or carboxy; and

R³ is hydrogen;

(2) A is selenium,

 R^1 is a sugar having the formula $(CHOH)_nCH_2OH$, where n is 1 to 5, or R^1 is an alkyl or aryl group, or R^1 is =0,

R² is hydrogen, R³ is COR⁵, wherein R⁵ is an alkoxy, or an amine group; or

(3) A is selenium,

 R^1 is a sugar having the formula (CHOH)_nCH₂OH, where n is 1 to 5, or R^1 is an alkyl or aryl group, or R^1 is =0,

R² is hydrogen, and R³ is hydrogen or COOH.

19. (previously presented) A method for (1) reducing unwanted side effects of chemo- or radiotherapy of cancer, (2) improving cardiovascular function, (3) preventing mutagenesis, (4) preventing the initiation and/or progression of cancer, (5) reducing toxic consequences of planned or unplanned radiation or chemical exposures, (6) slowing the aging process, or (7) preventing cataract formation in a mammal comprising administering the mammal a prodrug having the formula

$$R^1$$
 R^2
 R^3

wherein

(1) A is selenium,

 R^1 is a sugar having the formula (CHOH)_nCH₂OH, where n is 1 to 5, or R^1 is an

ATTORNEY DOCKET NO. 21101.0034U3 SERIAL NO. 10/051,463

alkyl or aryl group, or R¹ is =O,

R² is CH₂CH₂CH₂N(R⁴)₂, wherein R⁴ may be the same or different and may be hydrogen, alkyl, alkoxy, or carboxy; and

R³ is hydrogen;

(2) A is selenium,

 R^1 is a sugar having the formula $(CHOH)_nCH_2OH$, where n is 1 to 5, or R^1 is an alkyl or aryl group, or R^1 is =0,

R² is hydrogen, R³ is COR⁵, wherein R⁵ is an alkoxy, or an amine group; or

(3) A is selenium,

 R^1 is a sugar having the formula $(CHOH)_nCH_2OH$, where n is 1 to 5, or R^1 is an alkyl or aryl group, or R^1 is =0,

R² is hydrogen, and R³ is hydrogen or COOH.

20. (previously presented) A prodrug of the formula

where A is sulfur or selenium, and

R' is an alkyl or aryl group, or

R' is =0, and

R[‡] is an alkoxy, or an amine group.